



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,505	01/09/2006	Joerg Rosenberg	M/43212-US-1	4705
26474 7590 09/17/2007 NOVAK DRUCE DELUCA & QUIGG, LLP 1300 EYE STREET NW SUITE 1000 WEST TOWER WASHINGTON, DC 20005			EXAMINER CHO, JENNIFER Y	
			ART UNIT 1621	PAPER NUMBER
			MAIL DATE 09/17/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/539,505	<b>Applicant(s)</b> ROSENBERG ET AL.	
	<b>Examiner</b> Jennifer Y. Cho	<b>Art Unit</b> 1621	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 8/16/07.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 23-37 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 23-37 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>8/27/07</u> . | 6) <input type="checkbox"/> Other: _____  |

### **Detailed Action**

Receipt is acknowledged of the Response filed 8/16/2007.

The original claims 23-37 are pending in this application. Claims 1-22 have been cancelled.

### **IDS**

The information disclosure statement (IDS) filed on 8/27/2007 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

### **Claim Rejections – 35 USC 102**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 23 is rejected under 35 U.S.C. 102b as being anticipated by Boyer (US 4,800,079).

Boyer teaches a pharmaceutical composition of fenofibrate and a binder (abstract; column 3, line 17; column 4, line 22, claims 1 and 2). Therefore this claim is fully met.

### **Claim Rejections – 35 USC 103**

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 23-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over by Boyer (US 4,800,079), in view of Kothrade (US 6,284,803).

Boyer teaches a pharmaceutical composition of fenofibrate and a binder (abstract; column 3, line 17; column 4, line 22, claims 1 and 2).

Boyer is deficient in that the dependent limitations in claims 24-37 are not explicitly stated in the composition.

Kothrade et al. teaches a pharmaceutical formulation (column 14, line 45) in dosage form (column 1, line 4) comprising fenofibrate as the active ingredient (column 7, line 39), in the form of a molecular dispersion (column 10, line 48), and a polymeric binder composed of methyl methacrylate, acrylic acid, cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate (column 5, lines 11-13, 20-21) and other conventionally acceptable excipients (column 1, lines 4-7), which include flow regulators and silicates/silica gel (column 6, lines 1 and 12). The formulation is further obtainable by melt extrusion (column 2, line 8; column 5, line 35). The formulation has a ratio of free carboxyl groups to esterified carboxyl groups around 1:1, based on the weight percentage of methyl methacrylate to acrylic acid (column 2, lines 56-61) and the use of Eudragit types, which Applicant uses to exemplify this ratio preference (column 5, line

Art Unit: 1621

12; column 10, line 39) (see also specification page 7, lines 3-10). The formulation comprises 0.1 to 95%, preferably from 20 to 80%, in particular 30 to 70% by weight of the active substance (column 6, lines 61-63), with ranges of 15-83% for the binder (column 2, lines 19-45), in which the enteric binder (Eudragit types) is in the preferable range of up to 75% by weight of the binder component (column 4, lines 65-67; column 5, line 1 and 12) and with the range of up to 100%, in particular 0.02-50% of pharmaceutically/physiologically acceptable additives (column 5, lines 66-67; column 6, lines 7-8). The preceding percentages would include a formulation in which the content of active substance component relative to binder is from 20 to 30% by weight.

Kothrade further teaches that all three components of the formulation: fenofibrate, binder component and other excipients/additives, can be combined (column 1, lines 4-7; column 7, lines 10-12 and 39).

In reference to claim 37, which describes a method for oral administration, it is the position of the examiner that since the dosage is in tablet form (column 10, line 67), the expected mode of administration is orally. Additionally, Applicant states that fenofibrate is usually administered orally (specification page 1, line 15).

In reference to claim 25 and 26 which describes the binder as an enteric binder/enteric polymer, because the art describes the polymeric binder with the same components as Applicant's, which include methyl methacrylate, acrylic acid, cellulose, acetate phthalate and hydroxypropylmethylcellulose phthalate (column 5, lines 11-13, 20-21), it is the position of the Examiner that the enteric property is inherent to the binder/polymer composition.

Art Unit: 1621

Therefore, it would be prima facie obvious to one of ordinary skill in the art at the time of the invention, to combine the components of Kothrade for the formulation of Boyer to arrive at a fenofibrate composition for pharmaceutical oral administration. The expected result would be an effective lipid-regulating tablet in dosage form.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Y. Cho whose telephone number is (571) 272 6246. The examiner can normally be reached on 9 AM - 6 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (571) 272 0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1621

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Cho  
Patent Examiner  
Art Unit: 1621

for   
\_\_\_\_\_  
Yvonne Eyler  
Supervisory Patent Examiner  
Technology Center 1600